Free Trial

Pfizer (PFE) Stock Price, News & Analysis

+0.03 (+0.11%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
28.08 million shs
Average Volume
42.52 million shs
Market Capitalization
$161.84 billion
P/E Ratio
Dividend Yield
Price Target

Pfizer MarketRank™ Stock Analysis

Analyst Rating
2.40 Rating Score
25.6% Upside
$35.86 Price Target
Short Interest
1.10% of Shares Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.49mentions of Pfizer in the last 14 days
Based on 44 Articles This Week
Insider Trading
Proj. Earnings Growth
From $2.39 to $2.76 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

5.00 out of 5 stars

Medical Sector

2nd out of 922 stocks

Pharmaceutical Preparations Industry

2nd out of 416 stocks

PFE stock logo

About Pfizer Stock (NYSE:PFE)

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.


PFE Stock Price History

PFE Stock News Headlines

3 Stocks That Suddenly Drew in Options Traders
Options are complicated and not for the faint of heart. While some investors may use them to take on irresponsible leverage levels on their minor positions, others could use them to express their predictions on a particular stock.
3 Stocks That Suddenly Drew in Options Traders (PFE)
Three discounted stocks caught the attention of call option buyers last week, and they have Wall Street analysts to back them through double-digit upside.
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Biopharma giant Pfizer Inc. NYSE: PFE has given back all its COVID gains and more. Shareholders have sat through a painful two-year selloff from the stock's $61.71 high on December 20, 2021, to its swing low of $25.20 on April 26, 2024.
3 Bargain Stocks Near 52-week Lows
Markets were scared to wake up to the Federal Reserve (the Fed) pulling the rug. After pricing in the proposed interest rate cuts for 2024, which were set to be implemented by March, then May, and now September, according to the CME's FedWatch tool, markets retraced on the thought of no more cuts coming this year.
3 Bargain Stocks Near 52-week Lows (PFE)
Three undeniable bargains came into play after the market's disappointment sell off, investors still have double-digit upside ahead of them in these names
3 Healthcare Stocks to Buy Now: May 2024
3 Blue-Chip Stocks to Buy on the Dip: May 2024
3 Blue-Chip Stocks Set to Triple Soon
Pfizer (NYSE:PFE) Trading Down 1.3%
See More Headlines
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/1 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 6/14 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
$2.12 billion
Pretax Margin


Sales & Book Value

Annual Sales
$54.89 billion
Cash Flow
$2.97 per share
Book Value
$15.81 per share


Outstanding Shares
Free Float
Market Cap
$161.84 billion

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

PFE Stock Analysis - Frequently Asked Questions

Should I buy or sell Pfizer stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There are currently 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.
View PFE analyst ratings
or view top-rated stocks.

What is Pfizer's stock price target for 2024?

15 analysts have issued 1 year target prices for Pfizer's shares. Their PFE share price targets range from $27.00 to $50.00. On average, they predict the company's stock price to reach $35.86 in the next twelve months. This suggests a possible upside of 25.6% from the stock's current price.
View analysts price targets for PFE
or view top-rated stocks among Wall Street analysts.

How have PFE shares performed in 2024?

Pfizer's stock was trading at $28.79 on January 1st, 2024. Since then, PFE shares have decreased by 0.8% and is now trading at $28.56.
View the best growth stocks for 2024 here

When is Pfizer's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our PFE earnings forecast

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings results on Wednesday, May, 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.56 by $0.26. The biopharmaceutical company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive trailing twelve-month return on equity of 8.64% and a negative net margin of 0.56%. The business's revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.23 earnings per share.
Read the conference call transcript

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Wednesday, April 24th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share on Friday, June 14th. This represents a $1.68 dividend on an annualized basis and a yield of 5.88%. The ex-dividend date of this dividend is Thursday, May 9th.
Read our dividend analysis for PFE

Is Pfizer a good dividend stock?

Pfizer (NYSE:PFE) pays an annual dividend of $1.68 per share and currently has a dividend yield of 5.87%. PFE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for PFE.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY24 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of $2.15-2.35 for the period, compared to the consensus estimate of $2.21. The company issued revenue guidance of $58.5-61.5 billion, compared to the consensus revenue estimate of $59.94 billion.

What is Albert Bourla's approval rating as Pfizer's CEO?

358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Albert Bourla has an approval rating of 92% among the company's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.96%), Capital World Investors (1.99%), Bank of New York Mellon Corp (0.75%), Price T Rowe Associates Inc. MD (0.44%), Swiss National Bank (0.30%) and Van ECK Associates Corp (0.28%). Insiders that own company stock include Alexander R Mackenzie, Douglas M Lankler, Jennifer B Damico, John D Young, Pfizer Inc, Scott Gottlieb and William R Carapezzi Jr.
View institutional ownership trends

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Pfizer have any subsidiaries?
The following companies are subsidiares of Pfizer: AH Robins LLC, AHP Manufacturing B.V., Agouron Pharmaceuticals LLC, Alpharma Pharmaceuticals LLC, American Food Industries LLC, Amplyx Pharmaceuticals, Amplyx Pharmaceuticals Inc., Anacor Pharmaceuticals, Anacor Pharmaceuticals Inc., Angiosyn, Arena, Array BioPharma, Array BioPharma Inc., BIND Therapeutics Inc., Bamboo Therapeutics, Bamboo Therapeutics Inc., Baxter International - Marketed Vaccines, BioRexis, Bioren, Blue Whale Re Ltd., C.P. Pharmaceuticals International C.V., CICL Corporation, COC I Corporation, Catapult Genetics, Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Coley Pharmaceutical Group Inc., Covx, Cyanamid de Argentina S.A., Cyanamid de Colombia S.A., Distribuidora Mercantil Centro Americana S.A., Encysive Pharmaceuticals, Encysive Pharmaceuticals Inc., Esperion Therapeutics, Excaliard Pharmaceuticals, Farminova Produtos Farmaceuticos de Inovacao Lda., FoldRx Pharmaceuticals LLC, Foldrx Pharmaceuticals, Fort Dodge Manufatura Ltda., G. D. Searle & Co. Limited, G. D. Searle International Capital LLC, GI Europe Inc., GI Japan Inc., GenTrac Inc., Genetics Institute LLC, Hospira, Hospira Adelaide Pty Ltd, Hospira Australia Pty Ltd, Hospira Benelux BVBA, Hospira Holdings (S.A.) Pty Ltd, Hospira Inc., Hospira Limited, Hospira Philippines Inc., Hospira Pte. Ltd., Hospira Puerto Rico LLC, Hospira UK Limited, Hospira Worldwide LLC, Hospira Zagreb d.o.o., ICAgen, Idun Pharmaceuticals, InnoPharma, InnoPharma Inc., International Affiliated Corporation LLC, John Wyeth & Brother Limited, King Pharmaceuticals Holdings LLC, King Pharmaceuticals LLC, King Pharmaceuticals Research and Development LLC, Laboratoires Pfizer S.A., Laboratorios Pfizer Ltda., Laboratorios Wyeth LLC, Laboratorios Wyeth S.A., Laboratórios Pfizer Lda., MTG Divestitures LLC, Mayne Pharma IP Holdings (Euro) Pty Ltd, Medivation, Medivation Field Solutions LLC, Medivation LLC, Medivation Neurology LLC, Medivation Prostate Therapeutics LLC, Medivation Services LLC, Medivation Technologies LLC, Monarch Pharmaceuticals LLC, Neusentis Limited, NextWave Pharmaceuticals, P-D Co. LLC, PAH USA IN8 LLC, PBG Puerto Rico LLC, PF Argentum Acquisition ULC, PF Consumer Healthcare Holdings LLC, PF Consumer Healthcare Holdings US Inc., PF Czech Republic Holdings B.V., PF Finland Holdings B.V., PF OFG Ireland 2 B.V., PF OFG South Korea 1 B.V., PF OFG South Korea 2 B.V., PF PR Holdings C.V., PF PRISM C.V., PF PRISM Holdings B.V., PF PRISM IMB B.V., PFE Wyeth-Ayerst (Asia) LLC, PFIZER (VIETNAM) LIMITED COMPANY, PHIVCO Corp., PHIVCO Holdco S.à r.l., PIMB OFG Spain Holding S.L., PRISM Holdings B.V., PT. Pfizer Indonesia, Parke Davis & Company LLC, Parke Davis Limited, Parkedale Pharmaceuticals Inc., Peak Enterprises LLC, Pfizer, Pfizer (China) Research and Development Co. Ltd., Pfizer (Malaysia) Sdn Bhd, Pfizer (Perth) Pty Ltd, Pfizer (Thailand) Limited, Pfizer (Wuhan) Research and Development Co. Ltd., Pfizer AB, Pfizer AG, Pfizer AS, Pfizer Afrique de L'Ouest, Pfizer Anti-Infectives AB, Pfizer ApS, Pfizer Asia Manufacturing Pte. Ltd., Pfizer Australia Holdings B.V., Pfizer Australia Holdings Pty Limited, Pfizer Australia Investments Pty Ltd, Pfizer Australia Pty Ltd, Pfizer B.V., Pfizer Biopharma Egypt LLC, Pfizer Biopharmaceuticals Egypt LLC, Pfizer Bolivia S.A., Pfizer Canada ULC / Pfizer Canada SRI, Pfizer Chile S.A., Pfizer Cia. Ltda., Pfizer Colombia Spinco I LLC, Pfizer Consumer Healthcare, Pfizer Cork Limited, Pfizer Corporation Austria Gesellschaft m.b.H., Pfizer Corporation Hong Kong Limited, Pfizer Corporation S. de R.L., Pfizer Croatia d.o.o., Pfizer Deutschland GmbH, Pfizer Development B.V., Pfizer Development LLC, Pfizer Development LP, Pfizer Development Services (UK) Limited, Pfizer East India B.V., Pfizer Eastern Investments B.V., Pfizer Europe MA EEIG, Pfizer Export B.V., Pfizer Export Company, Pfizer Finance Share Service (Dalian) Co. Ltd., Pfizer France International Investments, Pfizer Free Zone Panama S. de R.L., Pfizer Global Holdings B.V., Pfizer Global Supply Japan Inc., Pfizer Global Trading, Pfizer Gulf FZ-LLC, Pfizer H.C.P. Corporation, Pfizer Health AB, Pfizer Health Solutions Inc., Pfizer Healthcare India Private Limited, Pfizer Healthcare Ireland, Pfizer Hellas A.E., Pfizer Himalaya Holdings Coöperatief U.A., Pfizer Holding France, Pfizer Holdings Corporation, Pfizer Holdings International Corporation, Pfizer Holdings International Luxembourg (PHIL) Sarl, Pfizer Inc., Pfizer Innovations AB, Pfizer Innovations LLC, Pfizer International LLC, Pfizer International Operations, Pfizer Investment Capital Unlimited Company, Pfizer Investment Co. Ltd., Pfizer Ireland PFE Holding 1 LLC, Pfizer Ireland PFE Holding 2 LLC, Pfizer Ireland Pharmaceuticals, Pfizer Ireland Ventures Unlimited Company, Pfizer Italia S.r.l., Pfizer Japan Inc., Pfizer Laboratories (Pty) Limited, Pfizer Laboratories Limited, Pfizer Leasing Ireland Limited, Pfizer Leasing UK Limited, Pfizer Limited, Pfizer Luxco Holdings SARL, Pfizer Luxembourg Global Holdings S.à r.l., Pfizer Luxembourg SARL, Pfizer MAP Holding Inc., Pfizer Manufacturing Austria G.m.b.H., Pfizer Manufacturing Belgium N.V., Pfizer Manufacturing Deutschland GmbH, Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG, Pfizer Manufacturing Holdings LLC, Pfizer Manufacturing Ireland Unlimited Company, Pfizer Manufacturing LLC, Pfizer Manufacturing Services, Pfizer Medicamentos Genericos e Participacoes Ltda., Pfizer Mexico Holding B.V., Pfizer New Zealand Limited, Pfizer North America Services LLC, Pfizer OTC B.V., Pfizer Overseas LLC, Pfizer Oy, Pfizer PFE AsiaPac Holding B.V., Pfizer PFE CIA. Ltda., Pfizer PFE Eastern Investments B.V., Pfizer PFE Global Holdings B.V., Pfizer PFE Pharmaceuticals Israel Holding LLC, Pfizer PFE Pharmaceuticals Israel Ltd., Pfizer PFE Service Company Holding B.V., Pfizer PFE Spain B.V., Pfizer PFE UK Holding 4 LP, Pfizer PFE İlaçları Anonim Şirketi, Pfizer Pakistan Limited, Pfizer Pharm Algerie, Pfizer Pharma GmbH, Pfizer Pharma PFE GmbH, Pfizer Pharmaceutical (Wuxi) Co. Ltd., Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC), Pfizer Pharmaceuticals Global B.V., Pfizer Pharmaceuticals Israel Ltd., Pfizer Pharmaceuticals Korea Limited, Pfizer Pharmaceuticals Science and Technology Co. Ltd., Pfizer Pigments Inc., Pfizer Polska Sp. z.o.o., Pfizer Private Limited, Pfizer Production LLC, Pfizer Products Inc., Pfizer Products India Private Limited, Pfizer R&D Holding B.V., Pfizer R&D Japan G.K., Pfizer R&D UK Limited, Pfizer Research (NC) Inc., Pfizer Romania SRL, Pfizer S.A., Pfizer S.A., Pfizer S.A. de C.V., Pfizer S.A.S., Pfizer S.G.P.S. Lda., Pfizer S.L., Pfizer S.R.L., Pfizer SA (Belgium), Pfizer SRB d.o.o., Pfizer Saudi Limited, Pfizer Service Company BVBA, Pfizer Service Company Ireland Unlimited Company, Pfizer Shared Services Unlimited Company, Pfizer Shareholdings Intermediate SARL, Pfizer Singapore Holding Pte. Ltd., Pfizer Specialties Limited, Pfizer Trading Polska sp.z.o.o., Pfizer Transactions LLC, Pfizer Tunisie SA, Pfizer Vaccines LLC, Pfizer Venezuela S.A., Pfizer Ventures (US) LLC, Pfizer Ventures LLC, Pfizer Worldwide Services Unlimited Company, Pfizer Zona Franca S.A., Pfizer spol. s r.o., Pharmacia, Pharmacia & Upjohn Company LLC, Pharmacia & Upjohn LLC, Pharmacia Brasil Ltda., Pharmacia Hepar LLC, Pharmacia Inter-American LLC, Pharmacia International B.V., Pharmacia LLC, Pharmacia Limited, PowderMed, Purepac Pharmaceutical Holdings LLC, ReViral, Redvax, Renrall LLC, Rinat Neuroscience, Rinat Neuroscience Corp., Roerig S.A., Searle Laboratorios Lda., Serenex, Servicios P&U S. de R.L. de C.V., Shiley LLC, Sinergis Farma-Produtos Farmaceuticos Lda., Solinor LLC, Sugen LLC, Tabor LLC, Therachon, Trillium Therapeutics, Trillium Therapeutics ULC, Trillium Therapeutics USA LLC, Upjohn Laboratorios Lda., Vicuron Holdings LLC, W-L LLC, Warner Lambert, Warner Lambert del Uruguay S.A., Warner-Lambert Company GmbH, Warner-Lambert Company LLC, Wyeth Ayerst Inc., Wyeth Ayerst S.à r.l., Wyeth Biopharma, Wyeth Farma S.A., Wyeth Holdings LLC, Wyeth Industria Farmaceutica Ltda., Wyeth LLC, Wyeth Lederle S.r.l., Wyeth Pakistan Limited, Wyeth Pharmaceuticals FZ-LLC, Wyeth Pharmaceuticals LLC, Wyeth Subsidiary Illinois Corporation, Wyeth Whitehall Export GmbH, Wyeth-Ayerst (Asia) LLC, Wyeth-Ayerst International LLC, and Wyeth-Ayerst Promotions Limited.
Read More
This page (NYSE:PFE) was last updated on 5/21/2024 by Staff

From Our Partners